SCHEMBL3202901

SCHEMBL3202901

CC(C)(C)OC(=O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.62
TSHR P16473 2/20 0.57
SLC2A1 P11166 1/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 4/20 0.56
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
ALDH1A1 P00352 2/20 0.54
GAA P10253 1/20 0.54
KDM4E B2RXH2 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
EGFR P00533 1/20 0.53
AURKB Q96GD4 1/20 0.53
RORC P51449 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14600409 0.94 MEN1 (0.66) HTTTSHRSLC2A1MEN1KMT2A
SCHEMBL5027770 0.92 HTT (0.54) HTTTSHRSLC2A1MEN1KMT2A
SCHEMBL14600412 0.91 HTT (0.60) HTTSLC2A1MEN1KMT2ASMN1; SMN2
SCHEMBL29666354 0.88 AR (0.49) HTTTSHRSLC2A1MAPTEGFR
SCHEMBL12228592 0.88 AR (0.49) HTTTSHRSLC2A1MAPTEGFR
SCHEMBL30681937 0.86 HPGD (0.51) HTTTSHRMEN1KMT2ASMN1; SMN2
SCHEMBL941486 0.86 HPGD (0.51) HTTTSHRMEN1KMT2ASMN1; SMN2
SCHEMBL16303890 0.86 EPHX1 (0.58) HTTMEN1KMT2ANPC1RAB9A
SCHEMBL15559868 0.85 HTT (0.52) HTTTSHRSLC2A1MEN1KMT2A
SCHEMBL3930649 0.84 MAPT (0.66) HTTTSHRSLC2A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048898-A1 Process for Synthesizing 7-Alkynyl-4- Aminoquinazolines and a Related Intermediate AVEO PHARMACEUTICALS, INC. 2010-02-25 US claimed
EP-2010183-A2 PROCESSES FOR SYNTHESIZING 7-ALKYNYL-4-AMINOQUINAZOLINES AND A RELATED INTERMEDIATE Aveo Pharmaceuticals, Inc. (US) 2009-01-07 EP claimed
WO-2007103233-A2 PROCESSES FOR SYNTHESIZING 7-ALKYNYL-4-AMINOQUINAZOLINES AND A RELATED INTERMEDIATE AVEO PHARMACEUTICALS, INC. (US) 2007-09-13 WO claimed
WO-2024222614-A1 HETEROCYCLIC GSPT1 DEGRADATION AGENT 北京诺诚健华医药科技有限公司 2024-10-31 WO disclosed
CN-116332905-A (S) -N-phenyl-1- (pyridin-2-yl) pyrrolidine-2-carboxamide derivatives 上海翊石医药科技有限公司 2023-06-27 CN disclosed
CN-109843892-B Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections 诺维拉治疗公司 2022-01-25 CN disclosed
US-20100048898-A1 Process for Synthesizing 7-Alkynyl-4- Aminoquinazolines and a Related Intermediate AVEO PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20100048898-A1 Process for Synthesizing 7-Alkynyl-4- Aminoquinazolines and a Related Intermediate AVEO PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20100048898-A1 Process for Synthesizing 7-Alkynyl-4- Aminoquinazolines and a Related Intermediate AVEO PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20100022467-A1 ANTI-CANCER PHOSPHONATE ANALOGS BOOJAMRA CONSTANTINE G 2010-01-28 US disclosed
US-20090181930-A1 KINASE INHIBITORY PHOSPHONATE ANALOGS CANNIZZARO CARINA 2009-07-16 US disclosed
WO-2007103233-A2 PROCESSES FOR SYNTHESIZING 7-ALKYNYL-4-AMINOQUINAZOLINES AND A RELATED INTERMEDIATE AVEO PHARMACEUTICALS, INC. (US) 2007-09-13 WO disclosed
WO-2007103233-A2 PROCESSES FOR SYNTHESIZING 7-ALKYNYL-4-AMINOQUINAZOLINES AND A RELATED INTERMEDIATE AVEO PHARMACEUTICALS, INC. (US) 2007-09-13 WO disclosed
CN-1267431-C Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2006-08-02 CN disclosed
US-20060046987-A1 Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2006-03-02 US disclosed
US-6919338-B2 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase ASTRAZENECA AB (SE) 2005-07-19 US disclosed
CN-1496364-A Substituted quinazoline derivatives and their use as inhibitors 2004-05-12 CN disclosed
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2003-10-02 US disclosed
EP-1299381-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS AstraZeneca AB (SE) 2003-04-09 EP disclosed
WO-2002000649-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS ASTRAZENECA AB (SE) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048898-A1 Process for Synthesizing 7-Alkynyl-4- Aminoquinazolines and a Related Intermediate CYP3A7, UGT2B7, UGT1A7 HTT 1043/4885TSHR 4628/4885SLC2A1 4562/4885
US-20090181930-A1 KINASE INHIBITORY PHOSPHONATE ANALOGS PIK3CA, PNKP, PIK3CB HTT 4357/4885TSHR 3334/4885SLC2A1 2326/4885
US-20100022467-A1 ANTI-CANCER PHOSPHONATE ANALOGS PIK3CA, PHOSPHO1, PTEN HTT 4035/4885TSHR 4311/4885SLC2A1 1703/4885
US-20060046987-A1 Substituted quinazoline derivatives and their use as inhibitors AURKA, AURKB, AURKC HTT 4307/4885TSHR 2960/4885SLC2A1 4435/4885
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors AURKA, AURKC, AURKB HTT 4535/4885TSHR 3868/4885SLC2A1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.